调节免疫抑制瘤微环境并通过STAT3路径阻塞抑制Mutp53-驱动CRPC的生长
Zichen Bian1, Jia Chen1, Yufan Wang1
1Department of Urology, The First Affiliated Hospital of Anhui Medical University; Institute of Urology, Anhui Medical University; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, 230022, China.
International journal of biological sciences
|May 19, 2025
概括
TP53突变,特别是p.R248Q,通过创建免疫抑制瘤微环境 (TME) 来驱动抵抗割的前列腺癌 (CRPC). 用抑制剂向STAT3途径可以减少这种免疫抑制并减缓CRPC的进展.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- TP53突变与癌症的进展有关,包括前列腺癌.
- 在前列腺癌患者中经常观察到TP53的p.R248Q变体.
- 了解突变p53 (mutp53) 在瘤微环境 (TME) 中的作用,对于开发有效疗法至关重要.
研究的目的:
- 研究TP53 p.R248Q突变对免疫抑制和割抵抗性前列腺癌 (CRPC) 进展的影响.
- 阐明涉及IL6/JAK2/STAT3通路的潜在机制.
- 评估针对CRPC中这种途径的治疗潜力.
主要方法:
- 通过CRISPR/Cas9基因编辑,在小鼠前列腺癌细胞中引入Trp53 p.R245Q突变,模仿人类TP53 p.R248Q.
- 将基因编辑细胞植入C57BL/6小鼠,以模拟CRPC进展和免疫相互作用.
- 用JAK2和STAT3抑制剂进行治疗,然后使用组织学,免疫光学,流细胞计,ELISA和生物信息学进行分析.
- 在C4-2人类前列腺癌细胞系中的验证.
主要成果:
- 在前列腺癌患者中,TP53突变,特别是p.R248Q,与总体和无复发生存率的减少有关.
- 基因编辑的mutp53细胞显示增加了扩散和瘤性.
- Mutp53瘤表现出IL6/JAK2/STAT3通路的激活,导致免疫抑制性TME,具有减少的促炎和增加的抗炎细胞因子.
- 发现Mutp53与SHP1在STAT3结合方面竞争,维持STAT3激活.
- STAT3抑制有效地降低了mutp53驱动的免疫抑制和瘤进展.
结论:
- 突变TP53,特别是p.R248Q变种,促进一种免疫抑制的TME,促进CRPC的进展.
- IL6/JAK2/STAT3信号通路是mutp53驱动的免疫逃避和瘤生长的关键媒介.
- 针对STAT3途径代表了对CRPC携带TP53突变的有前途的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


